- Home
- NMT vs PROK Comparison
NMT vs PROK Comparison
Compare NMT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- PROK
- Stock Information
- Founded
- NMT 1993
- PROK 2015
- Country
- NMT United States
- PROK United States
- Employees
- NMT N/A
- PROK N/A
- Industry
- NMT Finance/Investors Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMT Finance
- PROK Health Care
- Exchange
- NMT Nasdaq
- PROK Nasdaq
- Market Cap
- NMT 110.6M
- PROK 126.8M
- IPO Year
- NMT N/A
- PROK N/A
- Fundamental
- Price
- NMT $11.80
- PROK $0.91
- Analyst Decision
- NMT
- PROK Buy
- Analyst Count
- NMT 0
- PROK 4
- Target Price
- NMT N/A
- PROK $5.00
- AVG Volume (30 Days)
- NMT 19.1K
- PROK 479.2K
- Earning Date
- NMT 01-01-0001
- PROK 03-17-2025
- Dividend Yield
- NMT 3.21%
- PROK N/A
- EPS Growth
- NMT N/A
- PROK N/A
- EPS
- NMT N/A
- PROK N/A
- Revenue
- NMT N/A
- PROK $76,000.00
- Revenue This Year
- NMT N/A
- PROK N/A
- Revenue Next Year
- NMT N/A
- PROK N/A
- P/E Ratio
- NMT N/A
- PROK N/A
- Revenue Growth
- NMT N/A
- PROK N/A
- 52 Week Low
- NMT $9.05
- PROK $0.86
- 52 Week High
- NMT $10.93
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- NMT 53.11
- PROK 31.60
- Support Level
- NMT $11.72
- PROK $0.87
- Resistance Level
- NMT $11.78
- PROK $1.06
- Average True Range (ATR)
- NMT 0.09
- PROK 0.10
- MACD
- NMT -0.01
- PROK 0.01
- Stochastic Oscillator
- NMT 43.33
- PROK 18.75
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes by investing in a portfolio of municipal obligations issued by state and local government authorities within a single state or certain U.S. territories.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.